US Patent

US9499545 — Piperidinone carboxamide azaindane CGRP receptor antagonists

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2031-11-10 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects piperidinone carboxamide azaindane derivatives that are CGRP receptor antagonists for treating or preventing diseases like migraine.

USPTO Abstract

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3534 — Qulipta
U-2718 — Ubrelvy
U-2718 — Ubrelvy
U-3534 — Qulipta
U-3534 — Qulipta

Patent Metadata

Patent number
US9499545
Jurisdiction
US
Classification
Method of Use
Expires
2031-11-10
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.